Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for metabolic and endocrine disorders. Its clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. The company also focuses on the development of small molecule agonists of the thyroid receptor beta for adrenoleukodystrophy and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis. Viking Therapeutics was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
